Novadoz gets FDA green light for generic Rapaflo
Novadoz Pharmaceuticals has received the Food and Drug Administration’s clearance to market silodosin in 4-mg and 8-mg capsules.
The product is the generic of Allergan’s Rapaflo.
Silodosin is indicated for the symptomatic relief in men experiencing the condition benign prostatic hyperplasia.
The product is available in 4-mg 30 count bottles, and 8-mg 30 and 90 count bottles.
“Novadoz’s introduction of silodosin is the first of many DAY 1 generic launches for the organization. With our robust pipeline of high volume and niche generics, and our vertical integration of API, Product Formulation, and Finished Dosage Manufacturing, we look forward to building customer relationships based on that value proposition,” Novadoz president North America generics, Seshu Akula said.
The product is the generic of Allergan’s Rapaflo.
Silodosin is indicated for the symptomatic relief in men experiencing the condition benign prostatic hyperplasia.
The product is available in 4-mg 30 count bottles, and 8-mg 30 and 90 count bottles.
“Novadoz’s introduction of silodosin is the first of many DAY 1 generic launches for the organization. With our robust pipeline of high volume and niche generics, and our vertical integration of API, Product Formulation, and Finished Dosage Manufacturing, we look forward to building customer relationships based on that value proposition,” Novadoz president North America generics, Seshu Akula said.